Conditions

Once seen as a symptom, disrupted sleep is emerging as a modifiable driver of chronic illness. Drugmakers are targeting sleep pathways to reshape chronic disease biology, from pain to depression

Through training opportunities and re empowers community members to feel confident supporting refugees. From large private sector to local organizations the training offers information to build trusting relations with refugees and newcomers, in turn building resilience and encouraging clients and patients to seek help for physical and mental health challenges

SARASOTA, Fla.–(BUSINESS WIRE)–Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced that ‘512 met its primary and all secondary endpoints in a double-blind, placebo-controlled Phase 2 clinical study in adults with inadequately controlled CRSwNP (NCT06930612). ‘512 is known as BEL512 ex-China and CM512 in Greater China